[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Monocyte Activation Tests Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Source (PMBC and Cell Line), Products (MAT Kits and Reagents), and Application [Drug Development, Vaccine Development, Medical Devices, and Others (Research, etc.)]

December 2023 | 150 pages | ID: M2B7A2ABD2EEEN
The Insight Partners

US$ 5,190.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The monocyte activation tests market size was valued at US$ 65.174 million in 2022 and is expected to reach US$ 236.714 million by 2030; it is estimated to register a CAGR of 17.5% from 2022 to 2030.

The monocyte activation tests market analysis includes the study of market drivers such as a rise in patient safety concerns and a surge in demand for safer pyrogen testing methods in end-user industries such as pharmaceutical, biotech, and medical devices. Further, technological developments in monocyte activation test methods are anticipated to propel the monocyte activation tests market growth during the forecast period.

Based on the source, the monocyte activation tests market is bifurcated into PMBC and cell lines. The PMBC segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. Based on products, the monocyte activation tests market is bifurcated into MAT kits and reagents. The MAT kits segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. On the other hand, the reagents segment is anticipated to record a higher CAGR during the forecasted period. Based on application, the monocyte activation tests market is segmented into drug development, vaccine development, medical devices, and others (research, etc.). The drug development segment captured the largest share in 2022 and is expected to witness the same trend from 2022 to 2030.

The monocyte activation test detects potentiated cytokine release from the synergistic effect of endotoxin and non-endotoxin pyrogens. The monocyte activation test (MAT) is an in-vitro assay designed to test parenteral drugs, biologics, and medical devices for all classifications of pyrogens. Over the last five years, vaccines that previously used the Rabbit Pyrogen Test as their release assay has been among the initial adopters of the monocyte activation test (MAT). Moreover, unlike MAT, bacterial endotoxin tests are often unsuitable for intrinsically pyrogenic products or those that include additives commonly included in vaccines, such as aluminum hydroxide, which tend to interfere with the assay. A few instances of MAT's uptake in testing vaccines included Neisseria meningitidis vaccine, Hyperimmune Sera, Meningococcal vaccines, Yellow fever vaccine, Shigella sonnei vaccine, Rabies vaccine, Hepatitis B Vaccine, and Tick-borne encephalitis virus vaccine.

Source-based Insights

Based on the source, the monocyte activation tests market is bifurcated into PMBC and cell lines. The PMBC segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. The same segment is expected to witness a higher CAGR from 2022 to 2030. Currently, two commercialized monocyte activation test cell sources are available globally—the Mono-Mac-6 (MM6) cell line and Peripheral Blood Mononuclear Cells (PBMC). The MM6 derives from the blood of a single acute monocytic leukemia patient; as a result, the monocytes sometimes do not have TLRs that reflect the stable expression required to consistently detect pyrogenic contaminants and initiate the release of cytokines by a healthy human. Hence, the reproducibility of MAT results is low using this cell source. The Ph. Eur. (2.6.30) also describes MM6-based MAT kits as 'limited' in detecting non-endotoxin pyrogens.

On the other hand, PBMC-based MAT kits source their PBMC from the pooled blood of screened, healthy donors—which means that when incubated with a spiked product sample, the monocyte activation can assist the growth of a healthy human being. As a result, results for MAT kits based on this cell source have been consistently found to be reproducible. The Ph. Eur. (2.6.30) counts this cell source as proficient in detecting both endotoxins and non-endotoxin pyrogens.

Currently, three other commercialized PBMC-based monocyte activation test vendors are on the market. Each has a LoD of 0.125 EU/ml, 0.02 EU/ml, and 0.016 EU/ml. The CTL-MAT assay has a market-leading LoD of 0.004 EU/ml, making it the most sensitive monocyte activation test available worldwide.

Products-based Insights

Based on products, the monocyte activation tests market is bifurcated into MAT kits and reagents. The MAT kits segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. On the other hand, the reagents segment is expected to register a higher CAGR during the forecasted period.

Regional Analysis

The monocyte activation tests market is segmented based on region: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America captured the largest market share in 2022 and is expected to continue a similar trend during the forecast period, followed by Europe. Regulatory practices of monocyte activation tests by organizations such as United States Pharmacopeia (USP) and the Government of Canada have further fueled the overall growth of the monocyte activation tests market in the region. Also, increasing focus on patient safety concerns and improved healthcare outcomes is one factor aiding North America's market growth.

Merck KGaA, Darmstadt, Germany and/or its affiliates; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; Sanquin; and Lonza Group are among the leading companies operating in the monocyte activation tests market.

In October 2023, Lonza launched two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and ease rabbit-free pyrogen testing. The systems will replace Lonza’s traditional MAT system kit offerings, and the newly launched products contain the new PeliKine Human IL-6 Rapid ELISA Kit that minimizes hands-on time and reduces time-to-results from two days to two hours. The new tests give pharmaceutical and biotechnology manufacturers easier MAT testing options for product safety testing while helping to reduce the reliance on animals.

Some sources referred while conducting the monocyte activation tests market are Therapeutic Goods Administration, The Humane Society of the United States, and the National Institutes of Health, among others.
1. INTRODUCTION

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. EXECUTIVE SUMMARY

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. RESEARCH METHODOLOGY


4. MONOCYTE ACTIVATION TESTS MARKET LANDSCAPE

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
  4.3.1 List of Vendors in the Value Chain

5. MONOCYTE ACTIVATION TESTS MARKET - KEY MARKET DYNAMICS

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. MONOCYTE ACTIVATION TESTS MARKET - GLOBAL MARKET ANALYSIS

6.1 Monocyte Activation Tests - Global Market Overview
6.2 Monocyte Activation Tests - Global Market and Forecast to 2030

7. MONOCYTE ACTIVATION TESTS MARKET – REVENUE ANALYSIS (USD MILLION) – BY SOURCE, 2020-2030

7.1 Overview
7.2 PMBC
7.3 Cell Line

8. MONOCYTE ACTIVATION TESTS MARKET – REVENUE ANALYSIS (USD MILLION) – BY PRODUCTS, 2020-2030

8.1 Overview
8.2 MAT Kits
8.3 Reagents

9. MONOCYTE ACTIVATION TESTS MARKET – REVENUE ANALYSIS (USD MILLION) – BY APPLICATION, 2020-2030

9.1 Overview
9.2 Drug Development
9.3 Vaccine Development
9.4 Medical Devices
9.5 Others (Research etc.)

10. MONOCYTE ACTIVATION TESTS MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS

10.1 North America
  10.1.1 North America Monocyte Activation Tests Market Overview
  10.1.2 North America Monocyte Activation Tests Market Revenue and Forecasts to 2030
  10.1.3 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Source
  10.1.4 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Products
  10.1.5 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Application
  10.1.6 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Countries
    10.1.6.1 United States Monocyte Activation Tests Market
      10.1.6.1.1 United States Monocyte Activation Tests Market, by Source
      10.1.6.1.2 United States Monocyte Activation Tests Market, by Products
      10.1.6.1.3 United States Monocyte Activation Tests Market, by Application
    10.1.6.2 Canada Monocyte Activation Tests Market
      10.1.6.2.1 Canada Monocyte Activation Tests Market, by Source
      10.1.6.2.2 Canada Monocyte Activation Tests Market, by Products
      10.1.6.2.3 Canada Monocyte Activation Tests Market, by Application
    10.1.6.3 Mexico Monocyte Activation Tests Market
      10.1.6.3.1 Mexico Monocyte Activation Tests Market, by Source
      10.1.6.3.2 Mexico Monocyte Activation Tests Market, by Products
      10.1.6.3.3 Mexico Monocyte Activation Tests Market, by Application
Note - Similar analysis would be provided for below mentioned regions/countries
10.2 Europe
  10.2.1 Germany
  10.2.2 France
  10.2.3 Italy
  10.2.4 Spain
  10.2.5 United Kingdom
  10.2.6 Rest of Europe
10.3 Asia-Pacific
  10.3.1 Australia
  10.3.2 China
  10.3.3 India
  10.3.4 Japan
  10.3.5 South Korea
  10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
  10.4.1 South Africa
  10.4.2 Saudi Arabia
  10.4.3 U.A.E
  10.4.4 Rest of Middle East and Africa
10.5 South and Central America
  10.5.1 Brazil
  10.5.2 Argentina
  10.5.3 Rest of South and Central America

11. PRE AND POST COVID-19 IMPACT


12. INDUSTRY LANDSCAPE

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. COMPETITIVE LANDSCAPE

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. MONOCYTE ACTIVATION TESTS MARKET - KEY COMPANY PROFILES

14.1 Merck KGaA, Darmstadt,Germany and/or its Affiliates
  14.1.1 Key Facts
  14.1.2 Business Description
  14.1.3 Products and Services
  14.1.4 Financial Overview
  14.1.5 SWOT Analysis
  14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Charles River Laboratories International, Inc.
14.3 Thermo Fisher Scientific
14.4 Sanquin
14.5 Lonza Group
14.6 MAT Biotech
14.7 Cellmade Laboratories
14.8 Labor LS SE & Co. KG
14.9 BD Biosciences
14.10 Beckman Coulter

15. APPENDIX

15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud


More Publications